Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats

References

• Brown K, Comisar C, Witjes H, et al. (2017). Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer. Br J Clin Pharmacol 83:1216–26
   PubMed Web of Science ®Google Scholar
• Butler JM, Dressman JB. (2010). The developability classification system: application of biopharmaceutics concepts to formulation development. J Pharm Sci 99:4940–54
   PubMed Web of Science ®Google Scholar
• Calvert H, Twelves C, Ranson M, et al. (2014). Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer. Anticancer Drugs 25:832–40
   PubMed Web of Science ®Google Scholar
• Harandi A, Zaidi AS, Stocker AM, et al. (2009). Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol 2009:567486
   PubMedGoogle Scholar
• Kumarakulasinghe NB, Syn N, Soon YY, et al. (2016). EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. Oncotarget 7:85542–50
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, et al. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–703
   PubMed Web of Science ®Google Scholar
• Haruma K, Kamada T, Kawaguchi H. (2000). Effect of age and Helicobacter pylori infection on gastric acid secretion. J Gastroenterol Hepatol 15:277–83
   PubMed Web of Science ®Google Scholar
• Li J, Karlsson MO, Brahmer J, et al. (2006). CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst 98:1714–23
   PubMed Web of Science ®Google Scholar
• Lu JF, Eppler SM, Wolf J, et al. (2006). Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 80:136–45
   PubMed Web of Science ®Google Scholar
• Melosky B, Hirsh V. (2014). Management of common toxicities in metastatic NSCLC related to anti-lung cancer therapies with EGFR-TKIs. Front Oncol 4:238
   PubMedGoogle Scholar
• McCoach CE, Jimeno A. (2016). Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations. Drugs Today 52:561–8
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, et al. (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 11:121–8
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Sano K, Soda H, et al. (2010). Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. J Thorac Oncol 5:1404–9
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). (2017). Non-small cell lung cancer. Version 6. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf [last accessed 11 June 2017]
   Google Scholar
• Onoda S, Mitsufuji H, Yanase N, et al. (2005). Drug interaction between gefitinib and warfarin. Jpn J Clin Oncol 35:478–82
   PubMed Web of Science ®Google Scholar
• Pilotto A, Salles N. (2002). Helicobacter pylori infection in geriatrics. Helicobacter 7:56–62
   PubMed Web of Science ®Google Scholar
• Planchard D, Brown KH, Kim DW, et al. (2016). Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother Pharmacol 77:767–76
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals and Medical Devices Agency, Japan. (2017a). IRRESSA tablet package insert (in Japanese). Available from: 670227_4291013F1027_1_192_1F.pdf [last accessed 11 June 2017]
   Google Scholar
• Pharmaceuticals and Medical Devices Agency, Japan. (2017b). TARCEVA tablet package insert (in Japanese). Available from: 670227_4291013F1027_1_192_1F.pdf [last accessed 11 June 2017]
   Google Scholar
• Reichert JM, Valge-Archer VE. (2007). Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6:349–56
   PubMed Web of Science ®Google Scholar
• Rood JJ, van Bussel MT, Schellens JH, et al. (2016). Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 1031:80–5
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–50
   PubMed Web of Science ®Google Scholar
• Smelick GS, Heffron TP, Chu L, et al. (2013). Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm 10:4055–62
   PubMed Web of Science ®Google Scholar
• Swaisland HC, Ranson M, Smith RP, et al. (2005). Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 44:1067–81
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. (2017a). IRESSA (Gefitinib), Prescribing Information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206995s000lbl.pdf [last accessed 11 June 2017]
   Google Scholar
• US Food and Drug Administration. (2017b). TARCEVA (Erlotinib), Prescribing Information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021743s015lbl.pdf [last accessed 11 June 2017]
   Google Scholar
• US Food and Drug Administration. (2017c). TAGRISSO (osimertinib), Clinical Pharmacology and Biopharmaceutics Review(s). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208065Orig1s000Lbl.pdf [last accessed 14 October 2017]
   Google Scholar
• van Leeuwen RWF, van Gelder T, Mathijssen RHJ, et al. (2014). Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 15:e315–26
   PubMed Web of Science ®Google Scholar
• Wada I, Otaka M, Jin M, et al. (2006). Expression of HSP72 in the gastric mucosa is regulated by gastric acid in rats-correlation of HSP72 expression with mucosal protection. Biochem Biophys Res Commun 349:611–8
   PubMed Web of Science ®Google Scholar
• Zenke Y, Yoh K, Matsumoto S, et al. (2016). Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. Clin Lung Cancer 17:412–8
   PubMed Web of Science ®Google Scholar
• Zhao YY, Li S, Zhang Y, et al. (2011). The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. Med Oncol 28:697–702
   PubMed Web of Science ®Google Scholar